Talaris Therapeutics, Inc. (TALS)

Last Closing Price: 2.53 (2023-06-02)

Company Description

Talaris Therapeutics Inc. is a late-clinical stage cell therapy company. It involved in developing a method of allogeneic hematopoietic stem cell transplantation with the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders. Talaris Therapeutics Inc. is based in BOSTON.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-73.89M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.66
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -41.82%
Return on Assets (Trailing 12 Months) -39.37%
Current Ratio (Most Recent Fiscal Quarter) 16.59
Quick Ratio (Most Recent Fiscal Quarter) 16.59
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $4.33
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) $-1.66
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 42.01M
Free Float 35.08M
Market Capitalization $106.30M
Average Volume (Last 20 Days) 0.18M
Beta (Past 60 Months) 2.27
Percentage Held By Insiders (Latest Annual Proxy Report) 16.50%
Percentage Held By Institutions (Latest 13F Reports) 65.43%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%